Skip to menu Skip to content Skip to footer

2018

Journal Article

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Mathew, Nimitha R., Baumgartner, Francis, Braun, Lukas, O'Sullivan, David, Thomas, Simone, Waterhouse, Miguel, Müller, Tony A., Hanke, Kathrin, Taromi, Sanaz, Apostolova, Petya, Illert, Anna L., Melchinger, Wolfgang, Duquesne, Sandra, Schmitt-Graeff, Annette, Osswald, Lena, Yan, Kai-Li, Weber, Arnim, Tugues, Sonia, Spath, Sabine, Pfeifer, Dietmar, Follo, Marie, Claus, Rainer, Lübbert, Michael, Rummelt, Christoph, Bertz, Hartmut, Wäsch, Ralph, Haag, Johanna, Schmidts, Andrea, Schultheiss, Michael ... Zeiser, Robert (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 24 (3), 282-291. doi: 10.1038/nm.4484

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

2018

Journal Article

Flt-3L expansion of recipient CD8α+ dendritic cells deletes alloreactive donor T cells and represents an alternative to post-transplant cyclophosphamide for the prevention of GVHD

Markey, Kate A., Kuns, Rachel D., Browne, Daniel J., Gartlan, Kate H., Robb, Renee J., Martins, J. Paulo, Henden, Andrea S., Minnie, Simone A., Cheong, Melody, Koyama, Motoko, Smyth, Mark J., Steptoe, Raymond J., Belz, Gabrielle, Brocker, Thomas, Degli-Esposti, Mariapia A., Lane, Steven W. and Hill, Geoffrey R. (2018). Flt-3L expansion of recipient CD8α+ dendritic cells deletes alloreactive donor T cells and represents an alternative to post-transplant cyclophosphamide for the prevention of GVHD. Clinical Cancer Research, 24 (7), 1604-1616. doi: 10.1158/1078-0432.CCR-17-2148

Flt-3L expansion of recipient CD8α+ dendritic cells deletes alloreactive donor T cells and represents an alternative to post-transplant cyclophosphamide for the prevention of GVHD

2017

Journal Article

Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome

Varelias, Antiopi, Ormerod, Kate L., Bunting, Mark D., Koyama, Motoko, Gartlan, Kate H., Kuns, Rachel D., Lachner, Nancy, Locke, Kelly R., Lim, Chun Y., Henden, Andrea S., Zhang, Ping, Clouston, Andrew D., Hasnain, Sumaira Z., McGuckin, Michael A., Blazar, Bruce R., MacDonald, Kelli P. A ., Hugenholtz, Philip and Hill, Geoffrey R. (2017). Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome. Blood, 129 (15), 2172-2185. doi: 10.1182/blood-2016-08-732628

Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome

2015

Journal Article

Cytokines in graft-versus-host disease

Henden, Andrea S. and Hill, Geoffrey R. (2015). Cytokines in graft-versus-host disease. Journal of Immunology, 194 (10), 4604-4612. doi: 10.4049/jimmunol.1500117

Cytokines in graft-versus-host disease

2013

Journal Article

Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis

Henden, Andrea, Morris, Kirk, Truloff, Natasha, Nakagaki, Midori and Kennedy, Glen A. (2013). Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis. Leukemia and Lymphoma, 54 (6), 1329-1331. doi: 10.3109/10428194.2012.740561

Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis

2009

Journal Article

Myeloid and lymphoid neoplasm with FGFR1 abnormality

Keane, Colm, Henden, Andrea, Mills, Tony and Wood, Peter (2009). Myeloid and lymphoid neoplasm with FGFR1 abnormality. British Journal of Haematology, 145 (4), 440-440. doi: 10.1111/j.1365-2141.2008.07480.x

Myeloid and lymphoid neoplasm with FGFR1 abnormality

2009

Journal Article

Catastrophic tumour lysis syndrome following single dose of imatinib

Keane, Colm, Henden, Andrea and Bird, Robert (2009). Catastrophic tumour lysis syndrome following single dose of imatinib. European Journal of Haematology, 82 (3), 244-245. doi: 10.1111/j.1600-0609.2008.01186.x

Catastrophic tumour lysis syndrome following single dose of imatinib